NGL Fine Chem Ltd

NGL Fine Chem Ltd

₹ 1,243 -0.40%
22 Mar - close price
About

Established in 1981, NGL Fine-Chem Limited manufacturers and markets APIs, Intermediates and Finished Dosage forms for human and animal pharmaceutical product. It caters to various Indian and global companies with high quality and reliable products. [1]

Key Points

Product Portfolio
Presently, Veterinary APIs is the main product of the company which account for 88% of its revenues, followed by Veterinary Formulations (5%), Human APIs (4%), & Others (3%). [1]
24 APIs (22 veterinary, 2 human), 4 intermediates, 10 finished dosage forms
Leadership in top 5 products – 50%+ market share. [2]

  • Market Cap 768 Cr.
  • Current Price 1,243
  • High / Low 2,569 / 1,202
  • Stock P/E 39.6
  • Book Value 341
  • Dividend Yield 0.14 %
  • ROCE 34.7 %
  • ROE 28.9 %
  • Face Value 5.00

Pros

  • Company has delivered good profit growth of 28.5% CAGR over last 5 years
  • Company has a good return on equity (ROE) track record: 3 Years ROE 29.5%

Cons

  • Earnings include an other income of Rs.13.0 Cr.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Loading peers table ...

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

Dec 2019 Mar 2020 Jun 2020 Sep 2020 Dec 2020 Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022
37.42 35.48 42.42 68.21 72.79 71.79 75.91 78.50 81.37 78.21 62.94 64.95 69.80
33.57 33.27 29.83 49.49 50.98 50.96 52.78 61.96 69.32 68.22 63.47 60.20 62.37
Operating Profit 3.85 2.21 12.59 18.72 21.81 20.83 23.13 16.54 12.05 9.99 -0.53 4.75 7.43
OPM % 10.29% 6.23% 29.68% 27.44% 29.96% 29.02% 30.47% 21.07% 14.81% 12.77% -0.84% 7.31% 10.64%
1.27 0.91 2.25 2.85 3.65 2.53 4.92 4.89 4.41 2.28 3.65 4.10 2.95
Interest 0.64 0.60 0.60 0.54 0.37 0.33 0.37 0.40 0.42 0.37 0.50 0.12 0.26
Depreciation 1.88 1.86 1.87 1.81 1.86 1.85 1.93 1.96 1.90 1.88 1.96 2.02 2.00
Profit before tax 2.60 0.66 12.37 19.22 23.23 21.18 25.75 19.07 14.14 10.02 0.66 6.71 8.12
Tax % 21.92% 78.79% 28.46% 23.00% 24.62% 32.44% 24.85% 25.64% 23.20% 21.56% 24.24% 26.08% 25.00%
Net Profit 2.03 0.14 8.85 14.80 17.51 14.31 19.35 14.19 10.85 7.86 0.51 4.96 6.09
EPS in Rs 3.29 0.23 14.33 23.96 28.34 23.16 31.32 22.97 17.56 12.72 0.83 8.03 9.86
Raw PDF

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

Mar 2011 Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 TTM
35 36 56 79 88 96 100 114 153 152 258 319 276
30 32 48 68 73 74 74 92 121 129 181 253 254
Operating Profit 5 4 8 11 15 22 25 22 32 23 77 66 22
OPM % 14% 11% 14% 14% 17% 23% 26% 19% 21% 15% 30% 21% 8%
0 0 0 -1 2 0 1 3 4 1 9 13 13
Interest 1 1 1 2 2 2 1 2 3 3 2 2 1
Depreciation 1 1 2 2 3 3 3 5 6 7 7 8 8
Profit before tax 4 2 4 7 13 18 23 18 28 14 76 69 26
Tax % 37% 32% 35% 32% 35% 36% 35% 29% 27% 26% 27% 24%
Net Profit 2 1 3 5 8 11 15 13 20 11 55 52 19
EPS in Rs 3.92 1.70 4.71 7.33 13.48 18.45 24.10 20.38 32.58 17.16 89.79 84.57 31.44
Dividend Payout % -0% -0% -0% -0% -0% -0% -0% -0% 5% 10% 2% 2%
Compounded Sales Growth
10 Years: 24%
5 Years: 26%
3 Years: 28%
TTM: -10%
Compounded Profit Growth
10 Years: 48%
5 Years: 29%
3 Years: 37%
TTM: -67%
Stock Price CAGR
10 Years: 55%
5 Years: 25%
3 Years: 73%
1 Year: -36%
Return on Equity
10 Years: 27%
5 Years: 28%
3 Years: 30%
Last Year: 29%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

Mar 2011 Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Sep 2022
3 3 3 3 3 3 3 3 3 3 3 3 3
Reserves 13 14 17 21 30 41 56 69 89 98 152 203 208
6 10 13 17 13 14 23 27 27 28 16 30 27
9 10 14 15 21 19 20 31 23 26 34 41 39
Total Liabilities 32 37 47 56 67 78 102 129 142 156 206 278 276
11 10 18 19 17 24 25 56 61 61 58 59 61
CWIP 1 5 -0 -0 1 2 16 3 -0 -0 1 6 15
Investments 2 2 0 0 2 3 6 6 9 14 33 32 37
19 21 30 37 46 49 55 63 73 80 115 180 163
Total Assets 32 37 47 56 67 78 102 129 142 156 206 278 276

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

Mar 2011 Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022
4 1 -0 -0 8 8 10 22 9 20 27 13
-6 -4 -3 -4 -3 -10 -10 -21 -10 -19 -24 -13
1 3 4 3 -4 2 -0 -0 -0 -1 -1 -1
Net Cash Flow -0 -0 1 -1 1 0 -0 1 -1 -0 2 -1

Ratios

Standalone Figures in Rs. Crores / View Consolidated

Mar 2011 Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022
Debtor Days 112 115 100 110 107 123 110 89 79 63 53 74
Inventory Days 103 113 126 77 106 90 114 134 106 154 132 133
Days Payable 158 156 148 105 150 122 139 187 92 114 94 84
Cash Conversion Cycle 57 72 78 82 63 91 85 35 93 103 91 124
Working Capital Days 80 81 88 88 77 96 85 54 107 98 78 116
ROCE % 22% 11% 19% 24% 29% 37% 34% 22% 28% 15% 52% 35%

Shareholding Pattern

Numbers in percentages

8 recently
Mar 2020 Jun 2020 Sep 2020 Dec 2020 Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022
73.81 73.81 73.81 73.81 73.81 73.81 73.81 73.81 73.81 73.81 73.81 73.81
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.01 0.05 0.05 0.00
26.19 26.19 26.19 26.19 26.19 26.19 26.19 26.19 26.18 26.14 26.13 26.19

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents